Avidity Biosciences, Inc.

RNA

US05370A1088

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
25.14 ^USD	+4.06%		+5.14%	+177.79%

Apr. 04	Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing	MT
Apr. 04	Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing	MT

Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 3000 Growth Index

June 24, 2022 at 12:00 am EDT

Latest news about Avidity Biosciences, Inc.

Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing	Apr. 04	MT
Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing	Apr. 04	MT
Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding	Mar. 18	CI
Avidity Biosciences Insider Sold Shares Worth $980,760, According to a Recent SEC Filing	Mar. 15	MT
Cantor Fitzgerald Starts Avidity Biosciences With Overweight Rating, $60 Price Target	Mar. 14	MT
Transcript : Avidity Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:05 PM	Mar. 13
Avidity Biosciences Insider Sold Shares Worth $609,017, According to a Recent SEC Filing	Mar. 13	MT
Avidity Biosciences Insider Sold Shares Worth $1,691,306, According to a Recent SEC Filing	Mar. 05	MT
Chardan Ups Price Target on Avidity Biosciences to $33 From $23 on Efficacy, Safety DM1 Data, Keeps Buy Rating	Mar. 05	MT
Transcript : Avidity Biosciences, Inc. - Shareholder/Analyst Call	Mar. 04
Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor? Trial	Mar. 04	CI
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Apprehension About Key Inflation Data Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday	Feb. 29	MT
Avidity Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Avidity Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Avidity Biosciences, Inc. announced that it expects to receive $400.208766 million in funding	Feb. 27	CI
Avidity Biosciences Receives US FDA's Rare Pediatric Disease Designation for AOC 1044 in Duchenne Muscular Dystrophy	Feb. 20	MT
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping	Feb. 20	CI
Avidity Biosciences Appoints Strategy Chief, Plans to Start Phase 3 Myotonic Dystrophy Type 1 Study	Jan. 05	MT
Avidity Biosciences, Inc. Plans to Initiate the Global Phase 3 Harbour Trial of AOC 1001 for Adults Living with Myotonic Dystrophy Type 1, in Mid-2024	Jan. 05	CI
Avidity Biosciences, Inc. Announces Resignation of Eric Mosbrooker as Board of Directors and the Human Capital Management Committee of the Board	Jan. 05	CI
Avidity Biosciences Reports Positive Data Demonstrating Aoc 1044 Delivers Unprecedented Concentrations of Pmo in Muscle Following A Single Dose in Healthy Volunteers from Phase 1/2 Explore44? Trial for Duchenne Muscular Dystrophy	Dec. 13	CI
Sector Update: Health Care Stocks Ease Tuesday Afternoon	Nov. 28	MT
Sector Update: Health Care Stocks Decline Premarket Tuesday	Nov. 28	MT
Sector Update: Health Care	Nov. 28	MT

Chart Avidity Biosciences, Inc.

Duration

Period

More charts

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

Sector

Pharmaceuticals

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Avidity Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.16 USD

Average target price

46.71 USD

Spread / Average Target

+93.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
AVIDITY BIOSCIENCES, INC.	+177.79%	2.31B
CSL LIMITED	-2.68%	85.68B
SAMSUNG BIOLOGICS CO.,LTD.	+4.08%	41.4B
BIOGEN INC.	-25.35%	28.22B
UCB	+54.31%	24.64B
BIOMARIN PHARMACEUTICAL INC.	-4.52%	16.98B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.09%	13.29B
INCYTE CORPORATION	-17.77%	11.66B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.10%	11.65B
SWEDISH ORPHAN BIOVITRUM AB	+0.75%	8.18B

Biopharmaceuticals